Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
← catalyst calendarNCT05626855 · readout in 74 d
Sponsored by Scholar Rock, Inc. (industry) · SRRK — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
238actual
Sites
49
Countries
Belgium, France, Germany +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-17 | actual | When the study began enrolling |
| Primary completion | 2026-11-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-05-02 | estimated | The whole study's end, after follow-up |
| First posted | 2022-11-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Spinal Muscular Atrophy
- Spinal Muscular Atrophy Type 3
- Spinal Muscular Atrophy Type 2
- SMA
- Neuromuscular Diseases
- Muscular Atrophy
- Atrophy
- Muscular Atrophy, Spinal
- Neuromuscular Manifestations
- Anti-myostatin
Intervention
- Drug: Apitegromab
Primary outcome
what the primary-completion date above is the date OFEvaluate the long-term safety and tolerability of apitegromab in patients with Type 2 and Type 3 SMA
measured Up to 6 years
Permalink · SRRK's whole pipeline · Catalyst calendar · Every registered study · What changed